BioSante cites positive GVAX study, shares rise
BioSante cites positive GVAX study, shares rise
BioSante cites positive GVAX study, shares rise
BioSante PharmaceuticalsEvening Primrose Oil Softgel said Thursday that its GVAX cancer treatment led to a reduction of cancer cells in leukemia patients who had been taking the cancer drug Gleevec for at least one year.#x
In the study at the Johns Hopkins Kimmel Cancer Center, GVAX was given to 19 leukemia patients on Gleevec who had measurable cancer cells after at least one year. Cancer cells were reduced in 13 patients after a median of 72 months of follow-up. Patients remained on a stable dose of Gleevec.
The study was funded by the National Institutes of Health.
Shares of BioSante Pharmaceuticals ( BPA - news - people ) Inc. jumped 19 cents,google优化, #xor 11.11 percent, to $1.90 in afternoon trading. The stock has traded between $1.13 and $2.70 over the last 52 weeks.
Evening Primrose Oil Softgel
In October, BioSante completed its all-stock buyout valued at $38 million of Cell Genesys Inc. ( CEGE - news - people ), acquiring GVAX and other potential drugs in the process. Cell Genesys was developing GVAX as prostate cancer treatment,Evening Primrose Oil Softgel but discontinued testing as one trial was likely to fail and another had a high rate of patient deaths.
BioSante had said it would focus on pancreatic cancer,#x leukemia and breast cancer as potential indications for the drug.
相关的主题文章:
Leave a Comment
{ Last Page } { Page 26 of 274 } { Next Page }
|
About Me
Links
Categories
Recent Entries
Washington, Cal finish on high note 2 Americans and a third victim are killed in Mexic Non-Melanoma Skin Cancers in the Millions and Risi A Guide to This Week's Health Care Final Sprint The Girls Who Kicked in Rock’s Door
Friends
|